IVD Antibody Development Services for EG
Description
The latest results state that EGFR is a crucial mediator of tumor growth in non-small-cell lung cancer (NSCLC), which is linked to either excessive or improper signaling. Certain lung malignancies have been linked to EGFR mutations. Tyrosine kinase inhibitors (TKI)-responsiveness of malignancies may be partially determined by both EGFR mutation and gene amplification status. Therefore, in NSCLC, activating mutations in EGFR are significant indicators of responsiveness to TKI therapy. Furthermore, ALK rearrangements, MET immunohistochemistry, and the mutational status of KRAS and EGFR are significant biomarkers that are currently or soon will be useful in the diagnosis of lung cancer. IHC is a potential technique for identifying EGFR mutations to evaluate the EGFR marker abnormalities in NWeb page:
